Mr. Speaker, I would like to congratulate the member for introducing this bill in the effort to find a balance. I reflect on the debate we had between generic and non-generic drugs.
My question is similarly intended. The individuals who have come to see me who are opposed to this bill have indicated that in one particular respect, that is, the investment with respect to software proprietary rights and so on, there should be some consideration given to the manufacturers that have made those investments. Then there is the commercialization issue that comes into it. Could the member express how that balance similarly can be achieved through this bill?
The issue of training and safety has been brought forward. The member has talked a little about that, but does he think that training and safety will be placed at risk in terms of protection for the consumer?